What should I know first?
Donepezil inhibits acetylcholinesterase, an enzyme that breaks down the messenger acetylcholine. It illustrates a different way medicines can affect communication between cells.
The checked UK Aricept licence is for symptomatic treatment of mild to moderately severe Alzheimer’s dementia. This lesson does not import the broader US product wording, or present the drug as a treatment for every kind of forgetfulness.
This is a mechanism lesson, not a complete medicine guide. A diagram cannot choose treatment, predict your response, or tell you how to change a prescription.
How Brain Cells Communicate
Acetylcholine is a chemical messenger. After release, an enzyme called acetylcholinesterase helps break it down. An enzyme helps a chemical reaction occur; it is different from a receptor that responds to a messenger.
- Acetylcholine
The chemical messenger is the enzyme’s substrate.
- Acetylcholinesterase
An enzyme catalyzes breakdown; it is not a membrane transporter.
- Breakdown products
The two product symbols distinguish a chemical reaction from simple movement.
Simplified teaching model. Protein shapes, sizes, particle counts and arrows are illustrative, not measurements or experimental structures.
About this illustration
Acetylcholinesterase helps break down acetylcholine. The arrow represents a chemical reaction producing breakdown products, not movement through a transporter.
How the Medication Changes Signalling
Donepezil reversibly inhibits acetylcholinesterase. Slowing this breakdown can increase acetylcholine availability and support cholinergic signalling—the name for signalling using acetylcholine.
The illustration shows an enzyme process, not donepezil replacing acetylcholine or directly switching on every acetylcholine receptor. “Reversible” describes the inhibition; it does not mean that Alzheimer’s disease is reversed.
A Closer Look at the Molecular Level
Known action: reversible inhibition of acetylcholine breakdown is established in the pharmacology. The enzyme shape is symbolic rather than an experimental protein structure.
Clinical limitation: the label does not establish that donepezil changes the underlying disease process. Symptomatic treatment and curing or stopping degeneration are different claims. A diagram cannot predict how much an individual will benefit.
Sources and References
- Aricept 5 mg tablets: UK SmPC
Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.
Scope: United Kingdom.
- What Is a Neurotransmitter?
Scope: International scientific education; not UK regulatory evidence.
Article Information
- Edition
- United Kingdom
- Content updated
- 2026-10-17
- Sources checked
- Listed with each reference above; retained dates for shared scientific content.
- Publication status
- Published
- Scope
- How this medicine works, with UK product information.
Source and coverage limits
- A mechanism lesson is not a complete medicine profile, dosing schedule or individual treatment recommendation.
- Original qualitative SVG diagrams explain direction and target type; they do not measure biological rates, binding geometry or clinical response.

